Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiodesixBDSX +1.68%52 Equity-to-Asset is 0.10 as of Jun. 2026, which is at its 10-year median of 0.10. GuruFocus rates BDSX with a GF Score™ of 52/100 and a GF Value™ of $21.13 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Biodesix ranks worse than 89.05% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biodesix's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $9.1 Mil. Biodesix's Total Assets for the quarter that ended in Jun. 2026 was $95.3 Mil.
Therefore, Biodesix's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.10.
The historical rank and industry rank for Biodesix's Equity-to-Asset or its related term are showing as below:
BDSX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -5.48 Med: 0.1 Max: 0.34
Current: 0.1
During the past 8 years, the highest Equity to Asset Ratio of Biodesix was 0.34. The lowest was -5.48. And the median was 0.10.
BDSX's Equity-to-Asset is ranked worse than 89.05% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.595
vs BDSX: 0.10
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Biodesix Equity-to-Asset Related Terms
Biodesix Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Biodesix's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BDSX vs MYGN, XGN, IMDX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Biodesix's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biodesix Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Biodesix's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Biodesix's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biodesix (BDSX) has a Equity-to-Asset of 0.10 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Biodesix and its competitors. This is near median its historical median of 0.10. According to the industry distribution chart, Biodesix ranks #187 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 89%.
Is Biodesix's Equity-to-Asset too high?
Biodesix's current Equity-to-Asset of 0.10 is near median its 10-year median of 0.10. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.60. Biodesix's value of 0.10 is 83.2% below this industry median. Based on the distribution chart, Biodesix ranks #187 out of 210 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Biodesix has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biodesix's Equity-to-Asset compare to MYGN and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Biodesix ranks #187 out of 210 companies for Equity-to-Asset. This places Biodesix in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Biodesix's value of 0.10 is 83.2% below this benchmark. While the company's 10-year median is 0.10 vs. the industry median of 0.60, Biodesix has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.60, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biodesix's current Equity-to-Asset of 0.10 is 83.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Biodesix and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biodesix's current Equity-to-Asset is 0.10, which is near median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodesix stock overvalued right now?
Based on GuruFocus' analysis, Biodesix (BDSX) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.13, compared to a current price of $26.87 — trading 27.2% above its estimated fair value. The current Equity-to-Asset is 0.10, which is near median its 10-year median of 0.10 and 83.2% below the Medical Diagnostics & Research industry median of 0.60. Biodesix's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Biodesix (BDSX), the current Equity-to-Asset is 0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biodesix (BDSX) Overvalued in 2026?
Based on GuruFocus' analysis, Biodesix stock appears to be overvalued.
The current stock price of $26.87 is trading 27.2% above its estimated GF Value™ of $21.13.
GuruFocus considers Biodesix to be Modestly Overvalued.
Key valuation signals for BDSX:
Equity-to-Asset: 0.10 (near median its 10-year median of 0.10)
GF Value™: $21.13 vs. price of $26.87 (27.2% above fair value)
Industry Position: 83.2% below the Medical Diagnostics & Research median (#187 of 210)
No single metric tells the full story. See the BDSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
52GF Score
Get the complete analysis for BDSX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDSX has been successfully added to your 
